6533b861fe1ef96bd12c564b

RESEARCH PRODUCT

Effect of Treatment with rhGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes

Dieter HoelzerT. De WitteA. FerrantMarc BoogaertsB. LathanD. LutzJ. FrischPhilippe MartiatOliver G. OttmannG. VerhaefD. GangjiKlaus HöffkenRoland MertelsmannM. KlausmannO. KriegerReinhard BecherG. SchulzArnold GanserN. Van Der LellyVolker DiehlFriedhelm Herrmann

subject

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryCellular differentiationmedicine.medical_treatmentMyelodysplastic syndromesmedicine.diseaseLeukemiaGranulocyte macrophage colony-stimulating factorCytokineInternal medicinePrecursor cellImmunologyCytarabineMedicinebusinessmedicine.drug

description

Treatment of patients having myelodysplastic a syndromes (MDS) with approaches such as differentiation induction, single cytostatic agents or supportive care only has, up to now, been rather unsuccessful. Aggressive chemotherapy followed by bone marrow transplantation is only suitable for a very small proportion of patients. Thus, there is a need for new therapeutic alternatives.

yearjournalcountryeditionlanguage
1990-01-01
https://doi.org/10.1007/978-3-642-74643-7_138